Checkpoint inhibitors, such as nivolumab, are revolutionary new drugs in cancer therapy. Mild dermatologic toxicities are commonly reported adverse events. Herein, we highlight the development of the autoimmune blistering condition, bullous pemphigoid (BP) in a patient undergoing treatment with nivolumab. A 60-year-old man, who was being treated with nivolumab (3mg/kg intravenously every 2 weeks) after failing chemotherapy for metastatic renal cell carcinoma, presented acutely with a blistering rash. This article is protected by copyright. All rights reserved.
Journal of the European Academy of Dermatology and Venereology : JEADV. 2017 Jan 27 [Epub ahead of print]
Chase W Kwon, Anna S Land, Bruce R Smoller, Glynis Scott, Lisa A Beck, Mary Gail Mercurio
Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.